D. Boral Capital Reaffirms Buy Rating for Semper Paratus Acquisition (NASDAQ:TVGN)

Key Points

• The stock of Semper Paratus Acquisition (NASDAQ:TVGN) received a buy rating from D. Boral Capital, with a price target set at $10.00.
• CEO Ryan H. Saadi sold over 1.4 million shares of the company, reducing his stake by 1.22%, while insiders collectively hold 73.24% of the company's stock.
• Institutional investors have increased their positions, with notable investments from Barclays PLC and JPMorgan Chase & Co. during the fourth quarter.

Semper Paratus Acquisition (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reiterated by analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Semper Paratus Acquisition Stock Performance

Semper Paratus Acquisition stock traded up $0.03 during mid-day trading on Monday, reaching $0.90. The company's stock had a trading volume of 907,297 shares, compared to its average volume of 1,455,730. Semper Paratus Acquisition has a twelve month low of $0.26 and a twelve month high of $3.09. The business has a 50 day moving average price of $1.18 and a 200-day moving average price of $1.20.

Insiders Place Their Bets

In other news, CEO Ryan H. Saadi sold 1,438,206 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the completion of the transaction, the chief executive officer owned 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. The trade was a 1.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 73.24% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in shares of Semper Paratus Acquisition by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after purchasing an additional 16,695 shares during the period. Geode Capital Management LLC grew its stake in shares of Semper Paratus Acquisition by 31.2% in the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after purchasing an additional 107,566 shares in the last quarter. Barclays PLC increased its holdings in shares of Semper Paratus Acquisition by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after purchasing an additional 12,847 shares during the period. XTX Topco Ltd bought a new stake in shares of Semper Paratus Acquisition during the fourth quarter valued at about $55,000. Finally, Northern Trust Corp lifted its holdings in Semper Paratus Acquisition by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after purchasing an additional 13,595 shares during the period.

About Semper Paratus Acquisition

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.